LePure Biotech, a Shanghai, China-based provider of a bioprocessing platform, raised an undisclosed amount in Series C funding.
The round was led by Novo Holdings, General Atlantic and Goldman Sachs Asset Management, with participation from existing investors including Highlight Capital, Bayland Capital, and HM Capital.
The company intends to use the funds to accelerate product innovation, promote overseas expansion, and enhance its competitiveness in global industrial chain.
Led by Frank Wang, CEO, LePure Biotech provides a bioprocessing platform offering full-fledged product solutions that enable the manufacturing of macromolecular drugs. The company recently completed its acquisition of QuaCell Biotechnology, a cell culture media company, broadening product suite to bioprocessing consumables, bioreactors, filtration and purification solutions, as well as cell culture media offerings.
FinSMEs
17/01/2023